GlassScriptPhysician profile
Jeffrey S Fine
NPI 1649272816
$3,480.08
in general payments reported to CMS, 2019-2025
28 companies · $444 in 2025
The $444 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $612 · 2020: $936 · 2021: $312 · 2022: $288 · 2023: $693 · 2024: $196 · 2025: $444.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,301 · Education: $32.04.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,300.70 |
| Education | $32.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,088.80 | 2019-2025 | |
| Qol Medical, LLC | $585.77 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $402.46 | 2019-2021 | |
| Celgene Corporation | $202.19 | 2021-2023 | Zeposia |
| Intercept Pharmaceuticals, INC. | $151.14 | 2019-2023 | Ocaliva |
| Stryker Corporation | $140.82 | 2022 | |
| Allergan, INC. | $126.26 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $109.42 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $90.30 | 2023 | Zeposia |
| Merck Sharp & Dohme LLC | $75.55 | 2020-2023 | Dificid |
| Redhill Biopharma INC. | $65.30 | 2020-2022 | |
| Lilly USA, LLC | $55.26 | 2025 | Omvoh |
| Nestle Healthcare Nutrition INC. | $54.81 | 2022-2023 | |
| Vivus LLC | $41.37 | 2023-2025 | Qsymia |
| Phathom Pharmaceuticals, INC. | $38.89 | 2023 | Voquezna |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $33.40 | 2023 | |
| Janssen Biotech, INC. | $32.05 | 2021-2022 | |
| Vbi Vaccine (Delaware) INC. | $32.01 | 2023 | Prehevbrio |
| Shionogi INC | $30.75 | 2019 | |
| Baudax Bio INC. | $19.81 | 2020 | |
| Novo Nordisk INC | $17.16 | 2024 | Wegovy |
| Ironwood Pharmaceuticals, INC | $16.67 | 2020 | |
| Aimmune Therapeutics, INC. | $14.87 | 2025 | Zenpep |
| Daiichi Sankyo INC. | $14.67 | 2020 | |
| Alfasigma USA, INC. | $14.62 | 2020 | |
| Cumberland Pharmaceuticals, INC. | $14.10 | 2019 | |
| Micro-Tech Endoscopy USA, INC. | $11.63 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Fine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.